'Bi­ased and mis­lead­ing': No holds barred in FDA's sta­tis­ti­cal re­view of Bio­gen's Aduhelm

New FDA re­view doc­u­ments from the Aduhelm de­ci­sion re­leased Mon­day make clear why the agency’s own sta­tis­ti­cians dis­sent­ed on the con­tro­ver­sial ac­cel­er­at­ed ap­proval.

At the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER